AbbVie initiates pediatric study of Risankizumab for Ulcerative Colitis
A new study is underway to evaluate the safety and efficacy of Risankizumab in pediatric patients with moderate to severe Ulcerative Colitis.
Asset / Drug
Drug and asset intelligence for Risankizumab with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.